P53
P53 is a venture capital firm established in 2018 and located in Stavanger, Norway. The firm focuses on identifying and investing in innovative healthcare companies, with a particular emphasis on biotechnology and medical devices. By supporting emerging businesses in these sectors, P53 aims to foster advancements that can improve healthcare outcomes and drive industry growth.
2 past transactions
Calluna Pharma
Series A in 2024
Calluna Pharma is a clinical-stage company developing selective antibody therapies targeting immunological diseases. Its pipeline includes novel candidates addressing unmet clinical needs.
Teitur Trophics
Series A in 2023
Teitur Trophics is a biotech company established in 2020 and based in Aarhus, Denmark. The company specializes in the development of circular peptides aimed at addressing neurodegenerative diseases. Its research focuses on small peptides that interact with receptors central to neural function. By gaining insights into the biology of these receptors, Teitur Trophics aims to modulate key mechanisms in neural function, which may facilitate the creation of innovative treatments. These treatments are designed to be administered through daily injections, with the potential to prevent the onset of neurodegenerative conditions.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.